Genome Publications
https://doi.org/10.61096/978-81-981372-2-7_16

Chapter 16

Reproductive and Urogenital Pharmacology

Sumithira G
Professor, Department of Pharmacology, The Erode College of Pharmacy, Erode 638112, (Tamilnadu Dr.M.G.R.Medical university, Chennai)
Vallidevi S.D
Professor, Department of Obstetrics and Gynaecology, Madha Medical College & Hospital, Chennai 600128, (Tamilnadu Dr.M.G.R.Medical university, Chennai)
Krishnamoorthy B
Principal, Sanjivani College of Pharmaceutical Sciences, Khetri 333503
(Rajesthan University Health Sciences, Jaipur)

Abstract: Reproductive and urogenital pharmacology encompasses the pharmacological basis of therapies that target reproductive endocrinology, fertility modulation, sexual function, and lower urinary tract disorders. The field integrates hormonal regulation with drug discovery, addressing both male and female reproductive health. Hormonal contraceptives remain a cornerstone of family planning, involving estrogen-progestin combinations and progestin-only formulations, each with distinct mechanisms and risk-benefit profiles. Fertility treatments, including ovulation induction with clomiphene and gonadotropins, have advanced assisted reproductive technologies but pose complications such as ovarian hyperstimulation syndrome (OHSS). Androgen modulators such as testosterone therapy, anti-androgens, and 5α-reductase inhibitors play critical roles in conditions like hypogonadism, prostate cancer, and polycystic ovary syndrome (PCOS). Hormone replacement therapy (HRT) during menopause continues to raise debate over cardiovascular risks and cancer incidence, necessitating individualized approaches. Pharmacological interventions for benign prostatic hyperplasia (BPH), erectile dysfunction, and urinary incontinence highlight the relevance of α-blockers, phosphodiesterase-5 inhibitors, β3 agonists, and intravesical botulinum toxin. Finally, drug safety in pregnancy and lactation remains paramount, as teratogenic risks and FDA classifications guide therapeutic decision-making. This chapter provides a comprehensive analysis of these agents, emphasizing mechanisms, efficacy, clinical applications, limitations, and future perspectives in reproductive and urogenital pharmacology.

Keywords: reproductive pharmacology, hormonal contraceptives, fertility treatments, androgen modulators, urogenital therapeutics.

Citation: Sumithira G, Vallidevi S.D, Krishnamoorthy B. Reproductive and Urogenital Pharmacology *Modern Therapeutic Pharmacology: Precision Therapeutics Across Organ Systems.* Genome Publications. 2025; Pp166-176. https://doi.org/10.61096/978-81-981372-2-7_16

16.0 INTRODUCTION

Reproductive and urogenital pharmacology represents a highly dynamic branch of medical pharmacology concerned with drugs that act on the reproductive system and urinary tract. The pharmacological modulation of these systems has major implications for population health, fertility control, sexual function, and the management of urological disorders. These therapeutic strategies are inherently complex, given their reliance on intricate endocrine pathways, systemic hormonal regulation, and localized tissue responses. Both male and female reproductive systems are regulated by the hypothalamic-pituitary-gonadal (HPG) axis, where gonadotropin-releasing hormone (GnRH) stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. These hormones, in turn, regulate gonadal steroidogenesis and gametogenesis. Any pharmacological intervention in this system must consider potential downstream consequences on fertility, metabolism, cardiovascular health, and carcinogenesis [1].

The integration of reproductive pharmacology into clinical practice has transformed the management of conditions such as infertility, menopause, benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, and polycystic ovary syndrome (PCOS). Drugs such as selective estrogen receptor modulators (SERMs), gonadotropins, androgen modulators, and phosphodiesterase inhibitors represent milestones in therapeutic innovation. At the same time, concerns regarding teratogenicity, drug safety in pregnancy, and long-term adverse effects highlight the delicate balance between therapeutic efficacy and safety in this field [2].

In urogenital pharmacology, attention extends to lower urinary tract symptoms (LUTS), overactive bladder, and sexual dysfunction, with medications targeting adrenergic, cholinergic, and nitric oxide signaling pathways. Advances in pharmacogenomics are further shaping reproductive therapeutics, particularly in identifying patient-specific variations in estrogen metabolism or androgen receptor sensitivity, which may dictate drug efficacy and adverse effect profiles [3]. The chapter that follows systematically explores the pharmacology of reproductive and urogenital drugs, emphasizing mechanistic insights, clinical applications, comparative efficacy, safety considerations, and translational perspectives.

16.0.1 Hormonal Regulation of Reproduction

The hormonal regulation of reproduction is central to understanding the pharmacology of fertility control, androgen modulation, and assisted reproductive technologies. The hypothalamic-pituitary-gonadal axis orchestrates reproductive function through a pulsatile release of GnRH, which regulates the secretion of LH and FSH. LH stimulates Leydig cells in the testes to produce testosterone in men, while in women it promotes ovulation and corpus luteum formation. FSH plays a key role in spermatogenesis in men and follicular development in women [4].

Sex steroid hormones—estrogens, progesterone, and androgens—exert feedback regulation at both hypothalamic and pituitary levels. Pharmacological manipulation of these pathways forms the basis for contraceptive therapy, ovulation induction, and management of hormone-sensitive conditions such as prostate cancer and endometriosis [5]. Estrogens act primarily through estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), influencing reproductive tissue differentiation, bone density, and cardiovascular physiology. Progesterone, acting through progesterone receptors A and B, is crucial for preparing the endometrium for implantation and maintaining pregnancy. Androgens, predominantly testosterone and dihydrotestosterone (DHT), regulate secondary sexual characteristics, libido, and anabolic effects on muscle and bone [6].

Disruption of hormonal balance can lead to disorders such as PCOS, infertility, hypogonadism, and menopausal symptoms. Consequently, drugs targeting GnRH receptors (agonists and antagonists), gonadotropins, selective estrogen receptor modulators, aromatase inhibitors, and anti-androgens have been developed to modulate reproductive physiology. Importantly, these therapies must be tailored to individual hormonal milieus, as inappropriate modulation may exacerbate metabolic dysfunction, cardiovascular risk, or cancer susceptibility [7].

Advances in reproductive endocrinology have also expanded the scope of assisted reproductive technologies (ART), where exogenous gonadotropins, GnRH analogues, and luteal phase support are essential for successful in vitro fertilization (IVF). However, the risk of ovarian hyperstimulation syndrome (OHSS) highlights the need for careful pharmacological balancing [8]. In men, testosterone replacement therapy has gained prominence in managing late-onset hypogonadism, though concerns persist about its effects on cardiovascular outcomes and prostate health [9].

Ultimately, the hormonal regulation of reproduction serves as the foundation upon which reproductive pharmacology is built. An in-depth understanding of these pathways is essential for the rational development and safe clinical use of drugs in contraception, fertility management, and treatment of urogenital disorders.

16.1 Hormonal Contraceptives

Hormonal contraceptives are among the most widely studied and clinically applied pharmacological interventions in reproductive health. Their development transformed family planning, significantly reducing unintended pregnancies and contributing to maternal health improvement. Hormonal contraceptives act primarily through suppression of ovulation, alteration of cervical mucus, and endometrial modifications that impair implantation. Estrogen-progestin combinations and progestin-only formulations are the two principal categories, each with unique pharmacodynamics and safety considerations [10].

Combined estrogen-progestin contraceptives (COCs) inhibit ovulation by suppressing LH and FSH release through negative feedback on the hypothalamic-pituitary axis. The estrogen component, typically ethinylestradiol, stabilizes the endometrium, reducing breakthrough bleeding, while the progestin component, derived from 19-nortestosterone analogues, thickens cervical mucus and provides the dominant contraceptive effect [11]. Progestin-only methods, delivered as oral pills, injectables, or implants, are particularly useful in women with contraindications to estrogen, such as those with thromboembolic disease or uncontrolled hypertension [12].

The safety profile of COCs remains under debate. While highly effective, their use has been associated with an increased risk of venous thromboembolism, ischemic stroke, and, in certain populations, breast cancer [13]. However, they confer protective effects against ovarian and endometrial cancers, regulate menstrual cycles, and improve conditions such as acne and dysmenorrhea [14]. Long-acting reversible contraceptives (LARCs), such as levonorgestrel-releasing intrauterine systems, offer improved adherence and have been widely adopted in clinical practice [15].

Table 1: Comparative Features of Estrogen-Progestin and Progestin-Only Contraceptives

Feature	Estrogen-Progestin Combination	Progestin-Only Formulations
Primary mechanism	Suppresses LH/FSH surge, inhibits ovulation	Thickens cervical mucus, alters endometrium, inconsistently suppresses ovulation
Delivery methods	Oral pills, patch, vaginal ring	Pills, injectables, implants, IUDs
Advantages	Highly effective, regulates cycles, improves acne	Suitable in estrogen contraindication, safe during lactation
Risks	VTE, stroke, hypertension, breast cancer risk	Irregular bleeding, lower contraceptive efficacy (pills)
Protective effects	Reduces ovarian and endometrial cancer risk	Minimal impact on cancer risk



Figure 1: Pharmacological Regulation of Ovulation Induction

16.2 Fertility Treatments

Pharmacological interventions to promote fertility are essential for couples experiencing infertility, a condition affecting 10–15% of reproductive-aged populations globally. Ovulation induction remains a cornerstone of fertility treatment, utilizing drugs that target the HPG axis. Clomiphene citrate, a selective estrogen receptor modulator, is traditionally used to induce ovulation by antagonizing estrogen receptors at the hypothalamus, thereby releasing the negative feedback on GnRH secretion and increasing LH and FSH release [16]. Its widespread use has been supported by decades of clinical efficacy, particularly in women with polycystic ovary syndrome (PCOS).

Exogenous gonadotropins, including human menopausal gonadotropin (hMG) and recombinant FSH, represent more direct ovulation induction strategies, stimulating follicular

development in women unresponsive to clomiphene. These agents are integral to assisted reproductive technologies such as in vitro fertilization (IVF), where precise control of folliculogenesis is required [17]. GnRH agonists and antagonists are used to prevent premature LH surges during ovarian stimulation protocols, optimizing oocyte retrieval [18].

Despite these advances, fertility treatments carry risks. Ovarian hyperstimulation syndrome (OHSS), characterized by increased vascular permeability, ascites, and thromboembolic risk, remains a serious iatrogenic complication of gonadotropin use [19]. Additionally, multifetal pregnancies are more common, raising concerns about maternal and neonatal outcomes [20]. Adjuncts such as metformin in PCOS or letrozole, an aromatase inhibitor, have expanded therapeutic options with more favorable safety profiles [21].

16.3 Androgen Modulators

Androgen modulators form a diverse category of drugs targeting testosterone and dihydrotestosterone (DHT) signaling pathways. Their clinical applications span male hypogonadism, prostate cancer, benign prostatic hyperplasia (BPH), and female conditions such as PCOS. Testosterone replacement therapy (TRT) is widely prescribed for hypogonadal men, aiming to restore libido, bone density, muscle mass, and quality of life. Delivery systems include intramuscular injections, transdermal gels, buccal tablets, and subcutaneous implants [22].

However, TRT is not without controversy. Potential adverse effects include erythrocytosis, infertility due to suppression of endogenous spermatogenesis, prostate hypertrophy, and uncertain long-term cardiovascular risk [23]. Consequently, patient selection and monitoring of hematocrit, prostate-specific antigen (PSA), and lipid profiles are critical.

Anti-androgens represent the pharmacological counterpart, antagonizing androgen receptors or inhibiting androgen synthesis. Agents such as flutamide, bicalutamide, and enzalutamide are used in prostate cancer to suppress androgen-driven tumor growth [24]. In women with PCOS, anti-androgens like spironolactone reduce hirsutism and androgenic acne by blocking androgen receptors [25]. 5α-reductase inhibitors, such as finasteride and dutasteride, reduce DHT synthesis and are used in BPH and androgenic alopecia. By decreasing prostate volume, these agents relieve lower urinary tract symptoms and reduce the need for surgical intervention [26]. Despite their efficacy, sexual dysfunction, gynecomastia, and potential depression are notable side effects [27]. The balance between androgen replacement and suppression illustrates the dual nature of androgen pharmacology, emphasizing precision medicine approaches in tailoring therapy.

16.4 Menopause and Hormone Replacement Therapy

Menopause represents the permanent cessation of ovarian function, characterized by declining levels of estrogen and progesterone and the consequent end of reproductive capacity. The menopausal transition is accompanied by vasomotor symptoms such as hot flashes and night sweats, urogenital atrophy, osteoporosis, and increased cardiovascular risk. Hormone replacement therapy (HRT), consisting of estrogen alone or in combination with progestin, remains the most effective intervention for symptomatic relief. However, its use has been tempered by concerns about adverse long-term outcomes, particularly in relation to cardiovascular disease and cancer [28].

Estrogen therapy alleviates vasomotor symptoms and improves bone density, reducing the risk of osteoporotic fractures. When administered with progestin, endometrial hyperplasia and carcinoma are prevented in women with intact uteri. Nonetheless, large-scale studies such as the Women's Health Initiative (WHI) demonstrated an increased risk of breast cancer, stroke, and venous

thromboembolism with prolonged combined therapy [29]. The cardiovascular profile of HRT appears age-dependent, with initiation in younger postmenopausal women (within 10 years of menopause) possibly conferring cardioprotective effects, while later initiation may exacerbate vascular events [30].

Current clinical guidance emphasizes individualized therapy, balancing symptom control with minimization of risk. Non-hormonal alternatives, including selective serotonin reuptake inhibitors (SSRIs) and selective estrogen receptor modulators (SERMs), are considered when HRT is contraindicated.

Table 16.2: Benefits and Risks of Hormone Replacement Therapy

Benefits	Risks
Relief of vasomotor symptoms	Breast cancer (with prolonged combined therapy)
Improved bone density and fracture prevention	Venous thromboembolism and stroke
Reduction in colorectal cancer risk	Endometrial hyperplasia (with unopposed estrogen)
Improved urogenital health	Possible cardiovascular events depending on age and timing

16.5 Benign Prostatic Hyperplasia (BPH) and LUTS

Benign prostatic hyperplasia (BPH) is a prevalent condition in aging men, characterized by nonmalignant enlargement of the prostate gland and associated lower urinary tract symptoms (LUTS) such as hesitancy, weak stream, nocturia, and incomplete bladder emptying. Pharmacological management of BPH primarily involves α-adrenergic blockers and 5α-reductase inhibitors (5-ARIs) [31].

α-Blockers such as tamsulosin, alfuzosin, and doxazosin reduce smooth muscle tone in the bladder neck and prostate, rapidly relieving LUTS without significantly altering prostate size. They are generally well tolerated, though side effects such as dizziness, postural hypotension, and ejaculatory dysfunction are reported [32]. 5-ARIs, including finasteride and dutasteride, inhibit the conversion of testosterone to dihydrotestosterone (DHT), leading to gradual prostate shrinkage and disease modification. These agents reduce the risk of urinary retention and the need for surgical intervention but require several months to achieve efficacy [33].

Combination therapy offers superior outcomes in men with larger prostates and more severe symptoms. Emerging therapeutic approaches, including phosphodiesterase-5 inhibitors, are also being investigated for dual benefits in BPH and erectile dysfunction [34].

16.6 Erectile Dysfunction

Erectile dysfunction (ED), defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance, affects a significant proportion of men, particularly with advancing age and comorbidities such as diabetes, hypertension, and cardiovascular disease. The condition is strongly associated with endothelial dysfunction, impaired nitric oxide signaling, and cavernosal smooth muscle abnormalities [35].

Phosphodiesterase-5 (PDE5) inhibitors, including sildenafil, tadalafil, vardenafil, and avanafil, represent the first-line therapy for ED. These agents enhance cyclic guanosine monophosphate (cGMP)-mediated smooth muscle relaxation by inhibiting cGMP degradation, thereby augmenting nitric oxide-dependent vasodilation of penile arteries [36]. Their efficacy is well established across etiologies, though caution is required in patients on nitrates due to the risk of profound hypotension [37].

Emerging treatments include soluble guanylate cyclase stimulators, melanocortin receptor agonists, and regenerative strategies such as stem cell therapy and low-intensity shockwave therapy. The overlap between ED and cardiovascular disease underscores the importance of comprehensive risk factor modification.



Figure 16.2: Mechanism of Action of PDE5 Inhibitors

(Diagram showing nitric oxide release from endothelium → activation of guanylate cyclase → increased cGMP → smooth muscle relaxation and erection. PDE5 inhibitors prevent cGMP breakdown, sustaining erection.)

16.7 Urinary Incontinence

Urinary incontinence, the involuntary leakage of urine, is a common disorder with profound quality-of-life implications, particularly in women and the elderly. Overactive bladder syndrome, characterized by urgency and frequency, represents the most common pharmacological target.

Anticholinergics such as oxybutynin, tolterodine, and solifenacin act by inhibiting muscarinic receptors in the bladder detrusor muscle, reducing involuntary contractions. However, their clinical utility is often limited by side effects such as dry mouth, constipation, and cognitive impairment, particularly in older adults [38].

β3-adrenergic receptor agonists, including mirabegron, provide an alternative by promoting detrusor relaxation during filling, with improved tolerability. Intravesical botulinum toxin injections represent a third-line therapy for refractory cases, effectively reducing detrusor overactivity but requiring repeated administrations [39].

16.8 Pharmacogenomics in Reproductive Health

Pharmacogenomics is increasingly recognized as a cornerstone of personalized medicine in reproductive pharmacology. Variants in genes encoding estrogen-metabolizing enzymes, such as CYP3A4, CYP1A1, and COMT, influence both contraceptive efficacy and adverse event profiles [40]. For example, women with certain CYP3A5 polymorphisms may exhibit altered metabolism of ethinylestradiol, predisposing them to higher thromboembolic risk or reduced contraceptive reliability.

Similarly, genetic variation in androgen receptor (AR) sensitivity can modulate responses to anti-androgen therapy in prostate cancer or PCOS. Integration of pharmacogenomic testing into clinical practice holds the potential to optimize drug choice, dosing, and minimize adverse outcomes in reproductive health [41].

16.9 Drug Safety in Pregnancy

Medication use during pregnancy requires careful evaluation of maternal benefits against fetal risks. Teratogenicity, defined as drug-induced developmental abnormalities, is a major concern, particularly during organogenesis in the first trimester. Historically, the FDA categorized drugs into five groups (A, B, C, D, X), but this classification has been replaced by the Pregnancy and Lactation Labeling Rule (PLLR), which provides detailed risk summaries and clinical considerations [42].

Teratogenic drugs include isotretinoin, thalidomide, and certain anticonvulsants, whereas relatively safe options include insulin and many antibiotics such as penicillins and cephalosporins. Lactation safety must also be considered, as drugs can be excreted into breast milk and affect the neonate [43]. Clinicians must carefully balance maternal treatment needs with fetal safety, often opting for non-pharmacological alternatives when feasible.

CONCLUSION

Reproductive and urogenital pharmacology represents a diverse and evolving field that bridges endocrinology, reproductive biology, and urology. Through the development of hormonal contraceptives, fertility treatments, androgen modulators, and hormone replacement therapy, significant progress has been made in addressing both male and female reproductive health. The availability of pharmacological agents for benign prostatic hyperplasia, erectile dysfunction, and urinary incontinence has substantially improved patient quality of life, particularly in aging populations. At the same time, careful consideration is needed to balance therapeutic efficacy with the risks of adverse cardiovascular, metabolic, and neoplastic outcomes.

Advances in assisted reproductive technologies have broadened fertility options but introduced complications such as ovarian hyperstimulation syndrome and multifetal gestations, underscoring the importance of personalized approaches. Similarly, androgen therapy exemplifies both the benefits of restoring function in hypogonadal men and the risks of long-term use. In women, hormone replacement therapy provides substantial relief from menopausal symptoms, yet its cardiovascular and oncological implications demand individualized assessment.

The rise of pharmacogenomics offers a transformative avenue, enabling therapies tailored to genetic variations in hormone metabolism and receptor responsiveness. This promises to optimize efficacy while reducing risks in reproductive medicine. Moreover, the safety of pharmacotherapy during pregnancy and lactation remains a critical clinical challenge, as teratogenic potential continues to shape prescribing decisions.

In summary, reproductive and urogenital pharmacology has achieved substantial milestones but faces ongoing challenges in ensuring safety, precision, and accessibility. The integration of genomic

medicine, novel molecular targets, and improved safety frameworks will define the future trajectory of this field, reinforcing its role as a cornerstone of precision therapeutics across organ systems.

16.11 Future Perspectives

The future of reproductive and urogenital pharmacology will be shaped by precision therapeutics, regenerative medicine, and advances in molecular biology. Pharmacogenomic profiling is expected to transition from experimental research into routine clinical practice, enabling the tailoring of contraceptives, fertility drugs, and androgen modulators based on individual genetic signatures. This personalized approach may help mitigate risks such as thromboembolism in women using estrogen-based contraceptives or cardiovascular complications in men receiving testosterone therapy.

In fertility management, ongoing innovations in ovarian stimulation protocols, artificial gametogenesis, and embryo selection algorithms promise to improve the safety and success rates of assisted reproductive technologies. Novel agents targeting kisspeptin signaling and refined GnRH analogues may offer safer ovulation induction with lower risk of ovarian hyperstimulation syndrome. Additionally, stem cell–derived gametes and gene editing technologies may, in the long term, provide solutions for infertility that is currently irreversible.

In menopause management, the development of tissue-selective estrogen complexes and next-generation SERMs holds potential to provide symptomatic relief while minimizing cancer and cardiovascular risks. Similarly, novel androgen receptor modulators may provide therapeutic benefits in prostate disorders and PCOS without the adverse effects observed with current agents.

For urogenital disorders, ongoing research into β3 agonists, neuromodulators, and regenerative therapies, including stem cell–based bladder reconstruction and tissue-engineered urethral substitutes, may transform the treatment landscape for urinary incontinence and lower urinary tract dysfunction. Erectile dysfunction management is also advancing, with regenerative strategies such as gene therapy, stem cell transplantation, and low-intensity shockwave therapy offering restorative, rather than palliative, outcomes.

Finally, drug safety in pregnancy will continue to be a priority area. Advances in placental pharmacology, maternal–fetal medicine, and predictive modeling of teratogenic risk could provide clinicians with real-time decision-support systems, reducing uncertainty and improving maternal–fetal outcomes.

Overall, the next decades will likely see a paradigm shift from broad-spectrum hormonal manipulation toward individualized, regenerative, and safer approaches. The integration of genomics, biotechnology, and digital health platforms will ensure that reproductive and urogenital pharmacology evolves into a cornerstone of precision medicine and holistic patient care.

REFERENCES

1. Haisenleder DJ, Marshall JC. Regulation of the hypothalamic-pituitary-gonadal axis in humans. Endocr Rev. 2022;43(1):1–20.
2. Burger HG. The endocrinology of reproductive aging. J Clin Endocrinol Metab. 2019;104(9):3701–3714.
3. Zhang Y, Yang X, Song H, et al. Pharmacogenomics in reproductive medicine: Recent advances. Hum Reprod Update. 2021;27(3):451–468.
4. Plant TM. Neuroendocrine regulation of puberty. Nat Rev Endocrinol. 2021;17(1):29–44.

5. Archer DF. Estradiol and progesterone regulation of female reproductive function. Fertil Steril. 2019;112(1):12–25.
6. Davey RA, Grossmann M. Androgen physiology: Role in male and female health. Clin Biochem Rev. 2022;43(3):95–107.
7. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2019;394(10196):889–902.
8. Sunkara SK, Rittenberg V, Raine-Fenning N. IVF stimulation protocols: Balancing efficacy and safety. Fertil Steril. 2020;114(2):248–260.
9. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: Endocrine Society guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
10. Bitzer J, Simon JA. Current issues and emerging options in hormonal contraception. Eur J Contracept Reprod Health Care. 2020;25(2):104–112.
11. Sitruk-Ware R, Nath A. The use of newer progestins in contraception. Contraception. 2020;101(6):376–382.
12. Lopez LM, Grimes DA, Schulz KF. Progestin-only contraceptives: Effectiveness and side-effects. Cochrane Database Syst Rev. 2021;3:CD003989.
13. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism. BMJ. 2019;366:l4763.
14. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and oral contraceptives. Cancer Res. 2021;81(7):1735–1743.
15. Bahamondes L, Fernandes A, Monteiro I. Long-acting reversible contraceptives: Clinical performance. Hum Reprod Update. 2021;27(1):59–79.
16. Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and letrozole for ovulation induction. Cochrane Database Syst Rev. 2019;1:CD002249.
17. Fauser BCJM, et al. Recombinant gonadotropins in ovarian stimulation. Fertil Steril. 2019;112(3):498–507.
18. Depalo R, Trerotoli P, Chincoli A, et al. GnRH agonist vs antagonist protocols in IVF. Reprod Biomed Online. 2020;41(6):1084–1096.
19. Nastri CO, Teixeira DM, Moroni RM, et al. Ovarian hyperstimulation syndrome: Pathophysiology, prevention, and treatment. Fertil Steril. 2021;116(4):1028–1037.
20. Luke B. The risks of multifetal pregnancy. N Engl J Med. 2020;382(5):479–488.
21. Legro RS, et al. Letrozole vs clomiphene in PCOS. N Engl J Med. 2019;371(2):119–129.
22. Snyder PJ. Testosterone treatment: Indications and controversies. Annu Rev Med. 2020;71:507–522.
23. Traish AM. Adverse health risks of testosterone therapy in men. Aging Male. 2020;23(1):1–15.
24. Shore ND, Antonarakis ES, Cookson MS, Crawford ED. Next-generation androgen receptor pathway inhibitors in prostate cancer. Nat Rev Urol. 2021;18(1):26–42.
25. Moghetti P, Tosi F. Insulin resistance and PCOS: Therapeutic approaches including anti-androgens. Endocr Connect. 2021;10(9):R207–R221.
26. Roehrborn CG. 5α-reductase inhibitors in BPH: Clinical efficacy and safety. Urology. 2019;133:12–19.
27. Corona G, et al. Sexual dysfunction with 5α-reductase inhibitors. J Sex Med. 2020;17(4):647–654.
28. Stuenkel CA, Gass MLS, Manson JE, et al. A decade after WHI: The role of menopausal hormone therapy. J Clin Endocrinol Metab. 2019;104(5):1671–82.

29. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative. JAMA. 2002;288(3):321–33.
30. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause mortality. JAMA. 2017;318(10):927–38.
31. Gravas S, Cornu JN, Gacci M, et al. EAU Guidelines on the management of non-neurogenic male LUTS, including BPH. Eur Urol. 2022;81(1):75–94.
32. Chapple CR, Montorsi F, Tammela TL, et al. α-Blockers in BPH: Efficacy and safety revisited. BJU Int. 2020;125(2):213–25.
33. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med. 2003;349(25):2387–98.
34. Giuliano F, Roehrborn CG. Dual efficacy of tadalafil in LUTS and ED. Eur Urol. 2019;76(5):687–96.
35. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–41.
36. Kloner RA, Goldstein I, Kirby MG, et al. Pharmacology of PDE5 inhibitors in erectile dysfunction. J Sex Med. 2021;18(2):186–201.
37. Andersson KE. PDE5 inhibitors and cardiovascular interactions. Int J Impot Res. 2019;31(3):151–7.
38. Wagg A, Gibson W, Ostaszkiewicz J, et al. Pharmacological treatment of urinary incontinence in older people. Drugs Aging. 2020;37(1):1–14.
39. Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2019;202(3):558–63.
40. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease implications for reproductive pharmacology. Pharmacol Rev. 2021;73(2):364–89.
41. Fishel I, Goldstein DA. Pharmacogenomics of estrogen metabolism: Clinical implications. Clin Pharmacol Ther. 2020;108(2):205–15.
42. Food and Drug Administration. Pregnancy, lactation, and reproductive potential: Labeling for human prescription drug and biological products (PLLR). Fed Regist. 2014;79(233):72064–103.
43. Andrade SE, Raebel MA, Brown J, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf. 2021;30(2):203–12.